2014
A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. A 3′-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals Of Oncology 2014, 25: 2230-2236. PMID: 25081901, PMCID: PMC4207729, DOI: 10.1093/annonc/mdu367.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedCarcinoma, Squamous CellCetuximabCisplatinCyclin-Dependent Kinase Inhibitor p16Disease-Free SurvivalDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticGenotypeHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalPrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsSquamous Cell Carcinoma of Head and NeckConceptsNeck squamous cell carcinomaSquamous cell carcinomaKRAS-variantMetastatic headCell carcinomaPatient outcomesP16 expressionRecurrent/metastatic headPoor progression-free survivalCell linesM HNSCC patientsPlatinum-based regimenProgression-free survivalPotential predictive biomarkersHNSCC tumor samplesHNSCC cell linesTG/GGDrug resistance/sensitivityHNSCC patientsOropharynx tumorsClinical findingsRetrospective studyPredictive biomarkersClinical trialsPlatinum response
2013
Association of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Weidhaas J, Lee J, Slebos R, Howard J, Perez J, Gilbert J, Nallur S, Paranjape T, Garcia J, Burtness B, Forastiere A, Chung C. Association of the 3'-untranslated region KRAS-variant with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Journal Of Clinical Oncology 2013, 31: 6016-6016. DOI: 10.1200/jco.2013.31.15_suppl.6016.Peer-Reviewed Original ResearchNeck squamous cell carcinomaSquamous cell carcinomaKRAS-variantMetastatic headCell carcinomaP16/HPV statusRecurrent/metastatic headPoor progression-free survivalCisplatin resistanceHuman papillomavirus (HPV) statusProgression-free survivalTG/GGM HNSCCTumor DNA samplesHPV statusPatient demographicsHNSCC patientsClinical outcomesPoor outcomePoor prognosisPrognostic significancePredictive biomarkersClinical trialsProspective validationPromising biomarker